|March 19, 2013
Contact: Roz Hutchinson, 316-719-3343, email@example.com
Study seeks participants who’ve recently been treated for colon cancer
The Wichita Community Clinical Oncology Program, known as Wichita CCOP, is seeking participants for a polyp prevention study of people who have been recently treated for colon cancer. This National Cancer Institute-sponsored study evaluates the cholesterol-lowering drug rosuvastatin (sold under the brand name Crestor) as a treatment to reduce the risk of colon cancer.
The National Surgical Adjuvant Breast and Bowel Project, a network of cancer research professionals, is conducting the study titled, “P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer,” in which more than 400 medical centers throughout North America are participating.
“There will be an estimated 102,480 new cases of colon cancer in the United States this year,” said Norman Wolmark, MD, NSABP chairman. “In fact, colorectal cancer is the third most common cancer found in men and women in this country. We hope this trial will be an important step in reducing these numbers.”
The study was developed because laboratory research and studies conducted in large populations of patients taking a statin to reduce cholesterol suggest that taking the drug may also decrease the number of colon polyps. Colon polyps, if left untreated, can lead to colon cancer.
Already, more than 300 patients have entered the study that will eventually involve 1,740 patients who have been treated for early stage colon cancer and who were not already taking statins for high cholesterol. Patients will be randomly assigned to one of two groups. Each group will take one pill a day for five years. One group will receive rosuvastatin, while the other group will receive a placebo.
“We are seeing greater emphasis on prevention in our community, and we are making a difference in lives each day,” said Shaker Dakhil, MD, FACP, president of Cancer Center of Kansas and associate principal investigator for the Wichita CCOP.
People recently diagnosed or treated for Stage 0, I, II or III colon cancer and interested in the study should contact the Wichita CCOP at 316-262-4467.
Since its beginning more than 50 years ago, NSABP has enrolled more than 140,000 women and men in clinical trials in breast and colorectal cancer. NSABP has research sites at major medical centers, university hospitals, large oncology practice groups, and health maintenance organizations in the U.S., Canada, Puerto Rico, Australia and Ireland. At those sites and their satellites, more than 5,000 physicians, nurses and other medical professionals conduct NSABP treatment and prevention studies.
Via Christi Cancer Institute manages the grant funding for Wichita CCOP, which brings the latest cancer research to Kansas. Wichita CCOP is one of 63 programs sponsored and funded by the National Cancer Institute. Through relationships with such well-known programs as the M.D. Anderson Cancer Center in Houston and the Mayo Clinic in Rochester, Minn., and participating physicians nationwide, it offers patients the most current cancer research in detection, diagnosis, treatment, prevention, control and quality of life.